These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 25728286)

  • 21. Changing incidence trends of cutaneous T-cell lymphoma.
    Korgavkar K; Xiong M; Weinstock M
    JAMA Dermatol; 2013 Nov; 149(11):1295-9. PubMed ID: 24005876
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mycosis fungoides in the pediatric population: report from an international Childhood Registry of Cutaneous Lymphoma.
    Pope E; Weitzman S; Ngan B; Walsh S; Morel K; Williams J; Stein S; Garzon M; Knobler E; Lieber C; Turchan K; Wargon O; Tsuchiya A
    J Cutan Med Surg; 2010; 14(1):1-6. PubMed ID: 20128983
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of T-follicular helper markers in sequential biopsies of progressive mycosis fungoides and other primary cutaneous T-cell lymphomas.
    Bosisio FM; Cerroni L
    Am J Dermatopathol; 2015 Feb; 37(2):115-21. PubMed ID: 25406852
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Myocosis fungoides--an update on a non-mycotic disease.
    Makdisi J; Friedman A
    J Drugs Dermatol; 2013 Jul; 12(7):825-31. PubMed ID: 23884501
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cutaneous T-cell lymphoma: CT in evaluation and staging.
    Bass JC; Korobkin MT; Cooper KD; Kane NM; Platt JF
    Radiology; 1993 Jan; 186(1):273-8. PubMed ID: 8416579
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Review of contemporaneous mycosis fungoides and B-cell malignancy at Mayo Clinic.
    Herro E; Dicaudo DJ; Davis MD; Weaver AL; Swanson DL
    J Am Acad Dermatol; 2009 Aug; 61(2):271-5. PubMed ID: 19481294
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas.
    Klemke CD; Fritzsching B; Franz B; Kleinmann EV; Oberle N; Poenitz N; Sykora J; Banham AH; Roncador G; Kuhn A; Goerdt S; Krammer PH; Suri-Payer E
    Leukemia; 2006 Jun; 20(6):1123-9. PubMed ID: 16557241
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epidemiology and clinical manifestations of cutaneous T-cell lymphoma.
    Koh HK; Charif M; Weinstock MA
    Hematol Oncol Clin North Am; 1995 Oct; 9(5):943-60. PubMed ID: 8522490
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cutaneous T cell lymphoma: update on treatment.
    Wollina U
    Int J Dermatol; 2012 Sep; 51(9):1019-36. PubMed ID: 22909354
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation, Diagnosis, and Staging of Cutaneous Lymphoma.
    Olsen EA
    Dermatol Clin; 2015 Oct; 33(4):643-54. PubMed ID: 26433839
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of cutaneous lymphomas in a medical center in Bahia, Brazil.
    Bittencourt AL; Oliveira PD; Andrade AC; Santos TC; Oliveira RF; Farré L; Araujo I
    Am J Clin Pathol; 2013 Sep; 140(3):348-54. PubMed ID: 23955453
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The spectrum of cutaneous lymphomas in Japan: a study of 62 cases based on the World Health Organization Classification.
    Yasukawa K; Kato N; Kodama K; Hamasaka A; Hata H
    J Cutan Pathol; 2006 Jul; 33(7):487-91. PubMed ID: 16872471
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary cutaneous T-cell lymphoma: clinicopathological features and prognostic parameters of 35 cases other than mycosis fungoides and CD30-positive large cell lymphoma.
    Beljaards RC; Meijer CJ; Van der Putte SC; Hollema H; Geerts ML; Bezemer PD; Willemze R
    J Pathol; 1994 Jan; 172(1):53-60. PubMed ID: 7931828
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Morbidity and Causes of Death in Patients with Cutaneous T-cell Lymphoma in Finland.
    Väkevä L; Lipsanen T; Sintonen H; Ranki A
    Acta Derm Venereol; 2017 Jun; 97(6):735-738. PubMed ID: 28175924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nail irregularities associated with Sézary syndrome.
    Park K; Reed J; Talpur R; Duvic M
    Cutis; 2019 Apr; 103(4):E11-E16. PubMed ID: 31116823
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased malignancy risk in the cutaneous T-cell lymphoma patient population.
    Brownell I; Etzel CJ; Yang DJ; Taylor SH; Duvic M
    Clin Lymphoma Myeloma; 2008 Apr; 8(2):100-5. PubMed ID: 18501103
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incidence and survival patterns of cutaneous T-cell lymphomas in the United States.
    Imam MH; Shenoy PJ; Flowers CR; Phillips A; Lechowicz MJ
    Leuk Lymphoma; 2013 Apr; 54(4):752-9. PubMed ID: 23004352
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relative frequency of the different types of cutaneous T cell and natural killer cell lymphomas in Korea based on the proposed WHO classification and the EORTC classification.
    Chang SE; Jee MS; Kim KJ; Choi JH; Sung KJ; Moon KC; Koh JK
    J Dermatol; 2003 Jan; 30(1):42-7. PubMed ID: 12598708
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biological insights into the pathogenesis of cutaneous T-cell lymphomas (CTCL).
    Whittaker S
    Semin Oncol; 2006 Feb; 33(1 Suppl 3):S3-6. PubMed ID: 16516668
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence of primary cutaneous T-cell lymphoma in Norway.
    Saunes M; Nilsen TI; Johannesen TB
    Br J Dermatol; 2009 Feb; 160(2):376-9. PubMed ID: 18808419
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.